Page last updated: 2024-11-13

1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-O-palmitoyl-2-O-(5-oxovaleryl)-sn-glycero-3-phosphocholine : A 1,2-diacyl-sn-glycero-3-phosphocholine having palmitoyl and 5-oxovaleryl groups at the 1- and 2-positions respectively; major species at pH 7.3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID23557187
CHEBI ID77890
SCHEMBL ID244825
MeSH IDM0350271

Synonyms (25)

Synonym
pc(16:0/5:0(cho))
LMGP20010005
1-hexadecanoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphocholine
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine
povpc cpd
121324-31-0
povpc
pov-pc
SCHEMBL244825
(2r)-3-(hexadecanoyloxy)-2-[(5-oxopentanoyl)oxy]propyl 2-(trimethylazaniumyl)ethyl phosphate
1-hexadecanoyl-2-(5-oxopentanoyl)-sn-glycero-3-phosphocholine zwitterion
1-o-palmitoyl-2-o-(5-oxovaleryl)-sn-glycero-3-phosphocholine
(2r)-2-[(5-oxopentanoyl)oxy]-3-(palmitoyloxy)propyl 2-(trimethylammonio)ethyl phosphate
CHEBI:77890
1-hexadecanoyl-2-(5-oxopentanoyl)-sn-glycero-3-phosphocholine
RKIDALSACBQVTN-HHHXNRCGSA-N
2-(5-oxovaleryl)phosphatidylcholine
HMS3648A15
J-004479
DTXSID10634936
povpc, 1-palmitoyl-2-(5'-oxo-valeroyl)-sn-glycero-3-phosphocholine, powder
[(2r)-3-hexadecanoyloxy-2-(5-oxopentanoyloxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate
3,5,9-trioxa-4-phosphapentacosan-1-aminium, 7-[(1,5-dioxopentyl)oxy]-4-hydroxy-n,n,n-trimethyl-10-oxo-, inner salt, 4-oxide, (7r)-
3,5,9-trioxa-4-phosphapentacosan-1-aminium,7-[(1,5-dioxopentyl)oxy]-4-hydroxy-n,n,n-trimethyl-10-oxo-,innersalt,4-oxide,(7r)-
AKOS040754709

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The toxic lipid effects include inflammation and under sustained exposure apoptosis."( Toxicity of oxidized phosphatidylcholines in cultured human melanoma cells.
Hermetter, A; Hofmann-Wellenhof, R; Jaritz, H; Köfeler, H; Ramprecht, C; Schaider, H; Streith, I; Zenzmaier, E, 2015
)
0.42

Dosage Studied

ExcerptRelevanceReference
" We found a dose-response relationship for mGFP-GPI nanoplatform disintegration upon addition of POVPC, correlating with the signal of the apoptosis marker Annexin V-Cy3."( Oxidized Phospholipids Inhibit the Formation of Cholesterol-Dependent Plasma Membrane Nanoplatforms.
Brameshuber, M; Deigner, HP; Hermetter, A; Manner, C; Peksel, B; Péter, M; Rossboth, BK; Schütz, GJ; Sevcsik, E; Török, Z, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
1,2-diacyl-sn-glycero-3-phosphocholineThe conjugate base of a 1,2-diacyl-sn-glycero-3-phosphocholine compound formed by deprotonation of the phosphate OH group.
aldehydeA compound RC(=O)H, in which a carbonyl group is bonded to one hydrogen atom and to one R group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (60)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (3.33)18.2507
2000's34 (56.67)29.6817
2010's22 (36.67)24.3611
2020's2 (3.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.90 (24.57)
Research Supply Index4.13 (2.92)
Research Growth Index5.03 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.67%)5.53%
Reviews2 (3.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other57 (95.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]